Education
About Us
Working with TipRanks
Follow Us
Diamedica Therapeutics Inc (DMAC)
NASDAQ:DMAC
DMAC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.19 - $7.49
Previous CloseN/A
Volume70.76K
Average Volume (3M)420.04K
Market Cap
$376.30M
Enterprise Value$137.79M
Total Cash (Recent Filing)$30.04M
Total Debt (Recent Filing)$292.00K
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Nov 05, 2025EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding51,688,910
10 Day Avg. Volume615,899
30 Day Avg. Volume420,039
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.37
Enterprise Value/Revenue9.98
Enterprise Value/Gross Profit19.68K
Enterprise Value/Ebitda-4.43
Forecast
1Y Price Target
$13.00Price Target Upside83.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Clinical Study ResultsThe announcement of positive interim results from the Phase 2 preeclampsia study of DM199 showed statistically significant and clinically meaningful reductions in blood pressure, indicating potential therapeutic benefits.
Safety ProfileNo demonstrated placental transfer across all cohorts and no early labor inductions indicate critical safety for DM199, enhancing its profile for treating preeclampsia.
Therapeutic PotentialPositive interim results from Part 1a of the Phase 2 study show therapeutic potential of DM199 across achieved pre-specified efficacy and safety endpoints.
Bears Say
Market UncertaintyThe interim Phase 2 update has helped to de-risk the preeclampsia program, increasing confidence in the continuation of the trial.
Potential RisksDemonstrated safe placental perfusion and effect on blood pressure management in preeclampsia sets a supportive framework for potential stroke benefit.
Study ContinuationThe interim Phase 2 update provided de-risking for the PE program based on consistent demonstrated benefits, supporting trial continuation.
Diamedica Therapeutics News
DMAC FAQ
What was Diamedica Therapeutics Inc’s price range in the past 12 months?
Diamedica Therapeutics Inc lowest stock price was $3.19 and its highest was $7.49 in the past 12 months.
What is Diamedica Therapeutics Inc’s market cap?
Diamedica Therapeutics Inc’s market cap is $376.30M.
When is Diamedica Therapeutics Inc’s upcoming earnings report date?
Diamedica Therapeutics Inc’s upcoming earnings report date is Nov 05, 2025 which is in 51 days.
How were Diamedica Therapeutics Inc’s earnings last quarter?
Diamedica Therapeutics Inc released its earnings results on Aug 12, 2025. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.19 by $0.01.
Is Diamedica Therapeutics Inc overvalued?
According to Wall Street analysts Diamedica Therapeutics Inc’s price is currently Undervalued.
Does Diamedica Therapeutics Inc pay dividends?
Diamedica Therapeutics Inc does not currently pay dividends.
What is Diamedica Therapeutics Inc’s EPS estimate?
Diamedica Therapeutics Inc’s EPS estimate is -0.16.
How many shares outstanding does Diamedica Therapeutics Inc have?
Diamedica Therapeutics Inc has 51,688,910 shares outstanding.
What happened to Diamedica Therapeutics Inc’s price movement after its last earnings report?
Diamedica Therapeutics Inc reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.19. Following the earnings report the stock price went up 14.943%.
Which hedge fund is a major shareholder of Diamedica Therapeutics Inc?
Currently, no hedge funds are holding shares in DMAC
Diamedica Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.00 (83.36% Upside)
$13.00 (83.36% Upside)
Blogger Sentiment
Neutral
DMAC Sentiment 50%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $22.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 12.9%
Last 30 Days ▲ 26.6%
Last 30 Days ▲ 26.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.26%
12-Months-Change
Fundamentals
Return on Equity
-73.41%
Trailing 12-Months
Asset Growth
-44.59%
Trailing 12-Months
Company Description
Diamedica Therapeutics Inc
Diamedica Therapeutics (DMAC) is a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological and kidney diseases. The company leverages its expertise in therapeutic innovation to address unmet medical needs, primarily within the sectors of neurology and nephrology. Diamedica's core products include investigational therapies aimed at treating acute ischemic stroke and chronic kidney disease.
DMAC Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in DiaMedica's ongoing clinical programs, particularly in preeclampsia and stroke, alongside successful capital raising and strategic additions to the team and market indices. However, the company faces financial challenges with increased net losses and rising operational expenses.View all DMAC earnings summariesDMAC Stock 12 Month Forecast
Average Price Target
$13.00
▲(83.36% Upside)
Technical Analysis
Protara Therapeutics
―
Rezolute
―
Fulcrum Therapeutics
―
Tango Therapeutics
―
Inhibikase Therapeutics
―
Ownership Overview
47.05% Insiders
3.32% Mutual Funds
― Other Institutional Investors
45.62% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---